Published on 22/12/2025
How Tier-1 and Tier-2 Hospitals Shape Clinical Research in China
Introduction
China’s hospital system is at the core of its clinical trial ecosystem, with Tier-1 and Tier-2 hospitals playing distinct but interconnected roles. Tier-1 hospitals, often located in major urban centers such as Beijing, Shanghai, and Guangzhou, boast advanced infrastructure, experienced investigators, and established research networks, making them the primary choice for sponsors. Tier-2 hospitals, typically situated in provincial cities, provide access to broader patient populations but face challenges with staff expertise and research capacity. Understanding the differences between these tiers is essential for sponsors, CROs, and regulators seeking to expand clinical trial participation across China. As the National Medical Products Administration (NMPA) strengthens its regulatory oversight and pushes for broader site accreditation, the integration of both hospital tiers is becoming a strategic imperative for global and domestic sponsors. This article explores the roles of Tier-1 and Tier-2 hospitals in clinical research, their strengths and limitations, and best practices for balancing their contributions to successful trials.
Background and Regulatory Framework
Classification of Hospitals in China
China’s hospital system is categorized by tiers and grades. Tier-1 hospitals serve small communities, Tier-2 hospitals cover medium-sized
NMPA Site Accreditation
Historically, only a limited number of hospitals were authorized to conduct clinical trials in China. Since 2019, the NMPA has streamlined the site filing and accreditation process, enabling both Tier-1 and Tier-2 hospitals to qualify more quickly. This regulatory shift has expanded the pool of potential trial sites and supported greater patient access.
Case Example: Accreditation Reforms
The NMPA’s 2019 reforms reduced the time required for hospitals to gain trial accreditation from several years to a matter of months. This has encouraged Tier-2 hospitals to enter the clinical research space, although challenges in staffing and infrastructure persist.
Core Clinical Trial Insights
Infrastructure and Capacity
Tier-1 hospitals are equipped with cutting-edge facilities, electronic medical record systems, and dedicated research departments. They often handle high volumes of Phase I–III trials. Tier-2 hospitals, while having basic clinical services, may lack standardized research infrastructure, making them less suitable for early-phase or complex studies. Sponsors must carefully match trial complexity with site capacity.
Investigator Experience
Investigators at Tier-1 hospitals often have extensive experience with multinational trials and are familiar with ICH E6(R2) compliance. In contrast, Tier-2 hospitals face training gaps and limited exposure to international protocols. The NMPA emphasizes the need for ongoing GCP training and mentorship programs to address this imbalance.
Patient Recruitment and Diversity
Tier-1 hospitals, while prestigious, are saturated with trials competing for the same pool of patients. Recruitment delays are common, particularly in oncology and cardiovascular studies. Tier-2 hospitals provide access to less-studied patient populations, especially in rural and provincial regions, offering diversity that enhances the generalizability of trial results.
Ethics Review Committees
Tier-1 hospitals typically have well-established Institutional Review Boards (IRBs) with standardized processes, while Tier-2 hospitals may have limited ethics oversight capacity. To address this, the NMPA has promoted centralized ethics review pilots, which allow multicenter trials to benefit from consistent and expedited ethical evaluations.
Operational Efficiency
Sponsors often favor Tier-1 hospitals for their predictability and compliance track record. However, bottlenecks in scheduling, overworked staff, and bureaucratic layers can slow trial execution. Tier-2 hospitals, though less experienced, may offer faster enrollment once properly supported by CROs and trained staff.
Regional Disparities
China’s geographic size means that Tier-1 hospitals are concentrated in coastal cities, leaving western and rural regions underserved. Tier-2 hospitals in these areas play a vital role in extending trial access to patients who might otherwise be excluded. Expanding research capacity in these regions aligns with national goals of equitable healthcare access.
Best Practices & Preventive Measures
Sponsors should adopt a mixed-site strategy that leverages the strengths of Tier-1 hospitals while investing in the capacity building of Tier-2 hospitals. This includes providing GCP training, ensuring CRO support, and implementing phased mentorship programs. Feasibility assessments should evaluate infrastructure, staffing, and ethics oversight at both tiers to avoid recruitment bottlenecks and compliance risks.
Scientific & Regulatory Evidence
The NMPA’s site filing system and inspection regime are aligned with ICH E6(R2) on GCP. International precedents, such as FDA’s site inspection guidelines and EMA’s multi-site oversight models, reinforce the importance of robust training and capacity building across diverse hospital settings. Evidence from recent MRCTs demonstrates that integrating Tier-2 hospitals improves recruitment diversity without compromising data quality when proper oversight is applied.
Special Considerations
Certain therapeutic areas, such as pediatrics and rare diseases, require specialized infrastructure often limited to Tier-1 hospitals. Tier-2 hospitals may still play a role in long-term follow-up and safety studies. Sponsors should also consider cultural and linguistic diversity in provincial regions when designing trial materials for Tier-2 sites.
When Sponsors Should Seek Regulatory Advice
Sponsors planning to include Tier-2 hospitals in MRCTs should consult the NMPA early, particularly regarding accreditation status and ethics committee readiness. Regulatory consultations can help clarify expectations for oversight, monitoring, and CAPA implementation at newer trial sites.
Case Studies
Case Study 1: Oncology Trials in Beijing Tier-1 Hospitals
A multinational oncology trial conducted across three Tier-1 hospitals in Beijing experienced recruitment delays due to heavy competition. The sponsor added Tier-2 hospitals in neighboring provinces, which expanded patient access and shortened timelines by 25%.
Case Study 2: Cardiovascular Trial in Tier-2 Hospitals
A cardiovascular device study piloted in Tier-2 hospitals in Hunan province demonstrated that, with proper CRO support and training, Tier-2 sites could achieve high compliance rates. This trial became a benchmark for expanding beyond Tier-1 sites without compromising quality.
FAQs
1. What is the main difference between Tier-1 and Tier-2 hospitals in trials?
Tier-1 hospitals have advanced infrastructure and research capacity, while Tier-2 hospitals offer broader patient access but face training and resource limitations.
2. Can Tier-2 hospitals conduct Phase I trials?
Generally no, unless they have specialized infrastructure and NMPA accreditation. Tier-1 hospitals typically lead Phase I studies.
3. Why do sponsors still prefer Tier-1 hospitals?
Because of experienced investigators, established ethics committees, and predictable compliance, despite recruitment competition.
4. How does the NMPA support Tier-2 hospitals?
Through streamlined accreditation, centralized ethics review pilots, and capacity-building initiatives to increase trial participation.
5. Are patients in Tier-2 hospitals less willing to participate?
Not necessarily. Awareness may be lower, but with educational campaigns and physician support, participation rates can be strong.
6. What role do CROs play in supporting Tier-2 hospitals?
CROs provide essential training, monitoring, and operational support to help Tier-2 hospitals meet GCP standards and NMPA expectations.
Conclusion & Call-to-Action
The balance between Tier-1 and Tier-2 hospitals is critical for the success of clinical trials in China. While Tier-1 hospitals remain the backbone of research, Tier-2 hospitals represent the future of expanding access and improving patient diversity. Sponsors should strategically integrate both tiers into trial designs, invest in capacity building, and engage regulators early to ensure compliance. Building strong partnerships across tiers will not only improve recruitment timelines but also enhance the quality and inclusiveness of China’s clinical research landscape.